Literature DB >> 10864979

Direct immunomagnetic method for CD34+ cell selection from cryopreserved cord blood grafts for ex vivo expansion protocols.

S Querol1, G Capmany, C Azqueta, M Gabarró, O Fornas, G A Martín-Henao, J García.   

Abstract

BACKGROUND: Cord blood is a useful source of HPCs for allogeneic transplantation. HPC ex vivo expansion of a cord blood graft has been proposed as a way to increase the speed of engraftment and thus to reduce the occurrence of transplantation-related complications.
OBJECTIVE: The purpose of this study was to optimize a method for CD34+ cell selection of thawed cord blood grafts under clinical grade conditions, intended for application in a static, serum-free expansion culture.
MATERIAL AND METHODS: Twelve samples were thawed and washed with dextran, albumin, and rHu-deoxyribo-nuclease I (RHu-DNase) to avoid clumping. CD34+ cells were selected by using a sensitized immunomagnetic bead and 9C5 MoAb complex. A buffer containing rHu-DNase, citrate, albumin, and immunoglobulin in PBS was used during the procedure. CD34+ cells were eluted and detached by using an immunomagnetic cell selection device. Cells from the enriched fraction were cultured for 6 days in serum-free medium supplemented with rHu-SCF, rHu-IL-3, rHu fetal liver tyrosine kinase 3 ligand, and rHu thrombopoietin (50 ng/mL each). Cells were expanded in well plates and in two semipermeable bags.
RESULTS: A mean of 1.94 x 10(6) (+/- 1.55) CD34+ cells was obtained, yielding a CD34+ cell recovery of 52 +/- 12 percent. Nonspecific loss of CD34+ cells was 32 +/- 10 percent. CFU-GM and BFU-E/CFU-Mixed recoveries were 33 +/- 15 percent and 27 +/- 12 percent, respectively. CD34+ cells obtained were functionally comparable with fresh CD34+ cells selected for clonogenic potential. The capacity for expansion was not significantly different in the two types of bags studied. HPCs in wells were expanded 33 +/- 14-fold for CD34+ cells and 42 +/- 19-fold for overall colonies. The expansion rates observed in wells were significantly superior to those obtained in bags.
CONCLUSION: The feasibility of a clinical-scale cord blood selection procedure based on a direct immunomagnetic method after thawing, followed by an ex vivo expansion culture using semipermeable bags, is shown. After 6 days of expansion, it was possible to generate a 9-fold increase in CD34+ cells, a 6-fold increase in CFU-GM and a 13-fold increase in BFU-E/CFU-Mixed colonies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864979     DOI: 10.1046/j.1537-2995.2000.40060625.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Production of stem cells with embryonic characteristics from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz; M-O Baradez; S Navran; J Zhao; R Urban; R Tilton; L Denner
Journal:  Cell Prolif       Date:  2005-08       Impact factor: 6.831

Review 2.  Potential for access to embryonic-like cells from human umbilical cord blood.

Authors:  C P McGuckin; N Forraz
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 3.  Promising new sources for pluripotent stem cells.

Authors:  Christian Leeb; Marcin Jurga; Colin McGuckin; Richard Moriggl; Lukas Kenner
Journal:  Stem Cell Rev Rep       Date:  2010-03       Impact factor: 5.739

4.  Proliferation and differentiation potential of cryopreserved human skin-derived precursors.

Authors:  M Bakhtiari; K Mansouri; Y Sadeghi; A Mostafaie
Journal:  Cell Prolif       Date:  2012-01-20       Impact factor: 6.831

5.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.

Authors:  Jan Spanholtz; Frank Preijers; Marleen Tordoir; Carel Trilsbeek; Jos Paardekooper; Theo de Witte; Nicolaas Schaap; Harry Dolstra
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.